Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1425 of 3499 entries
View as:

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00408005 Org: User:
Start: 01/30/07 End: 03/31/25 Due: 03/31/26

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT06856226 Org: User:
Start: 07/02/25 End: 12/01/28 Due: 12/01/29

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04665739 Org: User:
Start: 02/03/23 End: 04/22/32 Due: 04/22/33

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Phase: N/A Priority: Normal
NCT ID: NCT05554328 Org: User:
Start: 04/25/23 End: 10/01/28 Due: 10/01/29

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase: N/A Priority: Normal
NCT ID: NCT04539366 Org: User:
Start: 01/25/22 End: 12/31/40 Due: 12/31/41

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Phase: N/A Priority: Normal
NCT ID: NCT06503146 Org: User:
Start: 07/02/25 End: 06/01/30 Due: 06/01/31

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04858334 Org: User:
Start: 06/22/21 End: 10/31/27 Due: 10/31/28

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Phase: N/A Priority: Normal
NCT ID: NCT05411081 Org: User:
Start: 03/24/23 End: 07/01/27 Due: 07/01/28

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase: N/A Priority: Normal
NCT ID: NCT04086485 Org: User:
Start: 10/03/22 End: 01/01/26 Due: 01/01/27

Collection of Tissue Samples for Cancer Research

Phase: N/A Priority: Normal
NCT ID: NCT00900198 Org: User:
Start: 07/06/06 End: - Due: -

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

Phase: N/A Priority: Normal
NCT ID: NCT03226704 Org: User:
Start: 08/14/17 End: 07/31/30 Due: 07/31/31

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase: N/A Priority: Normal
NCT ID: NCT04546399 Org: User:
Start: 12/17/20 End: 06/30/28 Due: 06/30/29

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01468311 Org: User:
Start: 10/11/11 End: 10/22/20 Due: 10/22/21

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00666562 Org: User:
Start: 07/02/08 End: 06/09/17 Due: 06/09/18

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00039676 Org: User:
Start: 07/08/02 End: - Due: -

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06904066 Org: User:
Start: 07/02/25 End: 04/30/29 Due: 04/30/30

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04708470 Org: User:
Start: 10/05/21 End: 12/01/26 Due: 12/01/27

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

Phase: N/A Priority: Normal
NCT ID: NCT01200680 Org: User:
Start: 01/02/11 End: - Due: -

Data Collection, Clinical Care and Interventions in CCR, NCI

Phase: N/A Priority: Normal
NCT ID: NCT00923065 Org: User:
Start: 06/10/04 End: - Due: -

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Phase: N/A Priority: Normal
NCT ID: NCT06096844 Org: User:
Start: 07/19/24 End: 06/01/26 Due: 06/01/27

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06410534 Org: User:
Start: 07/02/25 End: 09/01/32 Due: 09/01/33

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04579224 Org: User:
Start: 06/28/21 End: 08/15/30 Due: 08/15/31

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Phase: N/A Priority: Normal
NCT ID: NCT05327010 Org: User:
Start: 11/14/22 End: 12/31/26 Due: 12/31/27

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06690281 Org: User:
Start: 07/02/25 End: 06/30/33 Due: 06/30/34

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00050752 Org: User:
Start: 02/24/03 End: - Due: -